Bergen, Norway, 3 February 2022 - Reference is made to the stock exchange notice
published by BerGenBio ASA (the "Company") (OSE: BGBIO) on 27 January 2022 where
the Company announced that the board of directors of the Company had resolved to
increase the Company's share capital in connection with the exercise of options
pursuant to the Company's share option program. A total of 100,000 options were
exercised and 100,000 new shares were issued at an average subscription price of
NOK 15.33 per share.

The share capital increase has been duly registered in the Norwegian Register of
Business Enterprises. Following such registration, the Company's share capital
is NOK 8,855,525.50 divided into 88,555,255 shares, each with a nominal value of
NOK 0.10.

-End-

Contacts

Martin Olin

CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie

CFO, BerGenBio ASA

Rune.skeie@bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and
other important factors. Such risks, uncertainties, contingencies and other
important factors could cause actual events to differ materially from the
expectations expressed or implied in this announcement by such forward-looking
statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.